Amphista Therapeutics Achieves Breakthrough in Cancer Target Degradation
Amphista Therapeutics, a leader in next-generation targeted protein degradation (TPD), has published a study in Nature Communications demonstrating a novel mechanism for degrading the key cancer target BRD9 using its proprietary Targeted Glue small molecule degrader.
"The deep expertise of our scientists led to the successful integration of the favorable performance characteristics of earlier generation PROTACs and conventional molecular glues but with key limitations designed-out." - Louise Modis, PhD, Chief Scientific Officer at Amphista Therapeutics
The study showcases the company's innovative approach to targeted protein degradation, leveraging its novel Targeted Glue technology to achieve a new mechanism of action for BRD9 degradation.
Author's summary: Amphista Therapeutics publishes breakthrough study on cancer target degradation.